BAJAJ BROKING

Notification close image
No new Notification messages
card image
Euro Pratik Sales Ltd IPO
Apply for the Euro Pratik Sales Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

536565

NOVELIX

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NOVELIX PHARMACEUTICALS LIMITE Share Price Update

As of the latest trading session, NOVELIX PHARMACEUTICALS LIMITE share price is currently at ₹ 38, which is down by ₹ -1.00 from its previous closing. Today, the stock has fluctuated between ₹ 38.00 and ₹ 40.96. Over the past year, NOVELIX PHARMACEUTICALS LIMITE has achieved a return of 73.93 %. In the last month alone, the return has been -3.51 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

NOVELIX PHARMACEUTICALS LIMITE fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    55.20

  • P/E Ratio (TTM)

    97.72

  • Beta

    0.36

  • Book Value / share

    18.36

  • Return on equity

    0.56%

  • EPS (TTM)

    0.39

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.11

info icon alternate text

NOVELIX PHARMACEUTICALS LIMITE Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 22.35
Operating Expense 22.18
Net Profit 0.11
Net Profit Margin (%) 0.49
Earnings Per Share (EPS) 0.09
EBITDA 0.18
Effective Tax Rate (%) 35.29
Particulars MAR 2025 (Values in Cr)
Revenue 20.86
Operating Expense 20.65
Net Profit 0.18
Net Profit Margin (%) 0.86
Earnings Per Share (EPS) 0.18
EBITDA 0.22
Effective Tax Rate (%) 14.28
Particulars DEC 2024 (Values in Cr)
Revenue 5.30
Operating Expense 5.17
Net Profit 0.15
Net Profit Margin (%) 2.83
Earnings Per Share (EPS) 0.15
EBITDA 0.13
Effective Tax Rate (%) -15.38
Particulars SEP 2024 (Values in Cr)
Revenue 3.96
Operating Expense 3.74
Net Profit 0.13
Net Profit Margin (%) 3.28
Earnings Per Share (EPS) 0.16
EBITDA 0.13
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.60
Operating Expense 1.04
Net Profit -0.35
Net Profit Margin (%) -58.33
Earnings Per Share (EPS) -0.43
EBITDA -0.35
Effective Tax Rate (%) -2.85
Particulars MAR 2025 (Values in Cr)
Revenue 30.72
Operating Expense 30.61
Net Profit 0.08
Net Profit Margin (%) 0.26
Earnings Per Share (EPS) 0.08
EBITDA 0.16
Effective Tax Rate (%) 33.33
Particulars MAR 2024 (Values in Cr)
Revenue 4.22
Operating Expense 4.51
Net Profit 0.01
Net Profit Margin (%) 0.23
Earnings Per Share (EPS) 0.01
EBITDA 0.06
Effective Tax Rate (%) 50.00
Particulars MAR 2023 (Values in Cr)
Revenue 1.40
Operating Expense 1.98
Net Profit -0.06
Net Profit Margin (%) -4.28
Earnings Per Share (EPS) -0.07
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.84
Operating Expense 2.96
Net Profit -1.56
Net Profit Margin (%) -185.71
Earnings Per Share (EPS) -1.93
EBITDA -1.50
Effective Tax Rate (%) 0.63
Particulars MAR 2021 (Values in Cr)
Revenue 0.99
Operating Expense 4.58
Net Profit -3.27
Net Profit Margin (%) -330.30
Earnings Per Share (EPS) -4.04
EBITDA -3.19
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 9.14
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.01
EBITDA Margin -20.22
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.47
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.04
EBITDA Margin -36.18
Particulars MAR 2020 (Values in Cr)
Book Value / Share 13.09
ROE % -2.42
ROCE % -0.86
Total Debt to Total Equity 0.08
EBITDA Margin 0.92
Particulars MAR 2019 (Values in Cr)
Book Value / Share 13.48
ROE % -1.54
ROCE % -0.93
Total Debt to Total Equity 0.09
EBITDA Margin 1.00
Particulars MAR 2018 (Values in Cr)
Book Value / Share 13.79
ROE % -2.99
ROCE % -0.07
Total Debt to Total Equity 0.09
EBITDA Margin 2.16
Particulars MAR 2025 (Values in Cr)
Book Value / Share 17.63
ROE % 0.56
ROCE % 0.84
Total Debt to Total Equity 0.00
EBITDA Margin 0.52
Particulars MAR 2024 (Values in Cr)
Book Value / Share 9.08
ROE % 0.12
ROCE % 0.24
Total Debt to Total Equity 0.00
EBITDA Margin 1.42
Particulars MAR 2023 (Values in Cr)
Book Value / Share 8.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 8.94
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -107.19
Particulars MAR 2021 (Values in Cr)
Book Value / Share 10.87
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -243.51
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.88
Total Assets 8.73
Total Liabilities 8.73
Total Equity 7.67
Share Outstanding 8100000
Price to Book Ratio 0.99
Return on Assets (%) -20.60
Return on Capital (%) -23.05
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.07
Total Assets 9.57
Total Liabilities 9.57
Total Equity 7.36
Share Outstanding 8100000
Price to Book Ratio 0.62
Return on Assets (%) -39.06
Return on Capital (%) -50.77
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.11
Total Assets 13.72
Total Liabilities 13.72
Total Equity 11.12
Share Outstanding 8100000
Price to Book Ratio 0.13
Return on Assets (%) -2.06
Return on Capital (%) -2.38
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 0.19
Total Assets 13.34
Total Liabilities 13.34
Total Equity 11.42
Share Outstanding 8100000
Price to Book Ratio 0.00
Return on Assets (%) -1.81
Return on Capital (%) -1.96
Particulars MAR 2018 (Values in Cr)
Cash & Short Term Investments 0.35
Total Assets 13.57
Total Liabilities 13.57
Total Equity 11.57
Share Outstanding 8100000
Price to Book Ratio 0.52
Return on Assets (%) -2.56
Return on Capital (%) -2.77
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.67
Total Assets 27.20
Total Liabilities 27.20
Total Equity 17.53
Share Outstanding 9950000
Price to Book Ratio 1.51
Return on Assets (%) 0.31
Return on Capital (%) 0.48
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.11
Total Assets 7.36
Total Liabilities 7.36
Total Equity 7.35
Share Outstanding 8100000
Price to Book Ratio 1.89
Return on Assets (%) 0.14
Return on Capital (%) 0.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.27
Total Assets 7.25
Total Liabilities 7.25
Total Equity 7.19
Share Outstanding 8100000
Price to Book Ratio 1.01
Return on Assets (%) -0.82
Return on Capital (%) -0.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.60
Total Assets 7.25
Total Liabilities 7.25
Total Equity 7.24
Share Outstanding 8100000
Price to Book Ratio 0.99
Return on Assets (%) -21.51
Return on Capital (%) -21.54
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.73
Total Assets 8.76
Total Liabilities 8.76
Total Equity 8.80
Share Outstanding 8100000
Price to Book Ratio 0.62
Return on Assets (%) -37.28
Return on Capital (%) -37.13
Particulars MAR 2022 (Values in Cr)
Net Income -2.12
Cash from Operations 1.10
Cash from Investing -0.75
Cash from Financing 0.00
Net change in Cash 0.82
Free Cash Flow 2.90
Particulars MAR 2021 (Values in Cr)
Net Income -3.72
Cash from Operations 1.62
Cash from Investing 0.13
Cash from Financing -0.76
Net change in Cash 0.96
Free Cash Flow 1.64
Particulars MAR 2020 (Values in Cr)
Net Income -0.21
Cash from Operations 0.73
Cash from Investing 0.45
Cash from Financing -0.16
Net change in Cash 0.91
Free Cash Flow 0.83
Particulars MAR 2019 (Values in Cr)
Net Income -0.12
Cash from Operations -0.52
Cash from Investing 0.42
Cash from Financing -0.04
Net change in Cash -0.15
Free Cash Flow -0.38
Particulars MAR 2018 (Values in Cr)
Net Income -0.30
Cash from Operations 0.49
Cash from Investing -0.63
Cash from Financing 0.02
Net change in Cash -0.24
Free Cash Flow 0.86
Particulars MAR 2025 (Values in Cr)
Net Income 0.12
Cash from Operations -13.68
Cash from Investing 2.93
Cash from Financing 11.31
Net change in Cash 0.56
Free Cash Flow -13.57
Particulars MAR 2024 (Values in Cr)
Net Income 0.02
Cash from Operations -0.34
Cash from Investing 0.18
Cash from Financing 0.00
Net change in Cash -0.15
Free Cash Flow -0.34
Particulars MAR 2023 (Values in Cr)
Net Income -0.05
Cash from Operations -2.40
Cash from Investing 0.07
Cash from Financing 0.00
Net change in Cash -2.33
Free Cash Flow -2.40
Particulars MAR 2022 (Values in Cr)
Net Income -1.56
Cash from Operations 0.59
Cash from Investing 0.27
Cash from Financing 0.00
Net change in Cash 0.86
Free Cash Flow 2.45
Particulars MAR 2021 (Values in Cr)
Net Income -3.27
Cash from Operations 0.58
Cash from Investing 0.20
Cash from Financing 0.00
Net change in Cash 0.78
Free Cash Flow 0.88
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 30.69 12.53 1.68 235.19 30.00 / 68.00
BLISS GVS PHARMA LTD 150.55 14.91 1.51 1589.38 105.05 / 190.65
CIPLA LTD 1575.45 23.60 4.07 127257.62 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 336.80 9.48 2.73 991.24 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 30.69 16.68 4.84 235.19 30.00 / 68.00
AMRUTAJAN HEALTH LTD 765.70 40.60 6.77 2213.69 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 8938.20 105.66 29.00 22345.50 6222.35 / 10653.05
BLISS GVS PHARMA LTD 150.55 22.50 1.50 1589.38 105.05 / 190.65

NOVELIX PHARMACEUTICALS LIMITE Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
38.11 -2.30 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 39.50
  • 26 Days 40.60
  • 10 Days 40.10
  • 50 Days 39.70
  • 12 Days 40.20
  • 100 Days 35.30
  • 20 Days 40.50
  • 200 Days 28.00
39.67 PIVOT

First Support

38.35

First Resistance

40.34

Second Support

37.68

Second Resistance

41.66

Third Support

36.36

Third Resistance

42.33

RSI

41.23

ADX

26.58

MACD

-0.38

Williams % R

-98.28

Commodity Channel Index (CCI)

-174.00

Date

2025-09-19

Week

7003.00

Same Day

5237.00

Month

5086.00

1 Year

0.37

3 Year

-0.17

Over 1 Month

-3.51%

down

Over 1 Year

73.93%

down

Over 3 Months

29.93%

down

Over 3 Years

59.45%

down

Over 6 Months

43.21%

down

Over 5 Years

59.00%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

NOVELIX PHARMACEUTICALS LIMITE shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
47.25%
Promoter Holdings
52.74%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Srinidhi Fine-chemicals Llp 5002000.0 (38.67%) Shareholding of Promoter and Promoter Group
Mallela Venkatramna Reddy 1500000.0 (11.6%) Public Shareholding
Vupparapalli Chandrasekhar Reddy 870733.0 (6.73%) Shareholding of Promoter and Promoter Group
Vupparapalli Pavani 400000.0 (3.09%) Shareholding of Promoter and Promoter Group
Panchagnula Venkata Lakshmi Narayana Sankara Vara Prasad 375000.0 (2.9%) Public Shareholding
Tdpl Health Care (india) Llp 350000.0 (2.71%) Public Shareholding
Gattu Gnana Prakash 350000.0 (2.71%) Shareholding of Promoter and Promoter Group
Srinivasrao Swetha Kanakapur 300000.0 (2.32%) Public Shareholding
Sesha Sai Nikhil Chintalapati 300000.0 (2.32%) Public Shareholding
Soura Investments Holdings Private Limited 270000.0 (2.09%) Public Shareholding
Dm Fincon Services Llp 250000.0 (1.93%) Public Shareholding
Narhari Belide 200000.0 (1.55%) Shareholding of Promoter and Promoter Group
Medo Capital Services Private Limited 125000.0 (0.97%) Public Shareholding

News

Left Arrow
Right Arrow

NOVELIX PHARMACEUTICALS LIMITE corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
16 Aug 2012 0.3 Final 21 Aug 2012 Equity shares
22 Sep 2011 0.3 Final 25 Sep 2011 Equity shares
23 Aug 2010 0.03 Final 25 Aug 2010 Equity shares
01 Sep 2009 0.3 Final 03 Sep 2009 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
04 Oct 2010 1.0 10.0 05 Oct 2010
15 Oct 2009 10.0 1.0 16 Oct 2009

NOVELIX PHARMACEUTICALS LIMITE Share Price

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company. Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016.

Initially, the company was engaged in finance and investments in securities. They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company. Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

In November 2009, the Company received NS-EN ISO 9001:2008 / ISO 9001:2008 for marketing and distribution of pharmaceutical products from 'Kvalitet Veritas Quality Assurance'. They had been appointed as Authorized Distributors on all India level for Livewell Food products and ABLE, Pharma, in the Salon District of Himachal Pradesh.

During the year 2010-11, the Company started their first Pharmacy Retail Outlet in Himayath Nagar, Hyderabad. Also, they started their second retail outlet at Inderbagh, Sultan Bazar, Hyderabad. The Company with its full capacity commenced the business operations in food industry business through its wholly owned subsidiary in 2018.

The Company started their operations in State of West Bengal. Also, they started marketing of their products in Assam and with that they marked their presence in the eastern part of India.

Parent organization Indian Private
NSE symbol [-]
Founded 1994
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Novelix Pharmaceuticals Ltd?

Answer Field

Novelix Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 38.11 as on Sep 19 2025 03:29 PM.

What is the Market Cap of Novelix Pharmaceuticals Ltd Share?

Answer Field

The market cap of Novelix Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 55.20 as on Sep 19 2025 03:29 PM.

What is the 52 Week High and Low of Novelix Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Novelix Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 52.79 and ₹ 21.91.

What is 1 year return for Novelix Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 73.93%.

What is the P/E Ratio of Novelix Pharmaceuticals Ltd Share?

Answer Field

As on Sep 19 2025 03:29 PM the price-to-earnings (PE) ratio for Novelix Pharmaceuticals Ltd share is 97.72.

What is the PB ratio of Novelix Pharmaceuticals Ltd Share?

Answer Field

As on Sep 19 2025 03:29 PM, the price-to-book (PB) ratio for Novelix Pharmaceuticals Ltd share is 18.36.

How to Buy Novelix Pharmaceuticals Ltd Share?

Answer Field

You can trade in Novelix Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Novelix Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Novelix Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Novelix Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91